GlassScriptPhysician profile
Hui Ling Chen
NPI 1215554266
$5,897.13
in general payments reported to CMS, 2019-2025
25 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,267 · 2022: $888 · 2023: $992 · 2024: $1,590 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,961 · Education: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,961.41 |
| Education | $781.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,106.16 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $952.03 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $746.14 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $391.13 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $385.68 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $384.31 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $278.93 | 2021-2024 | |
| Ucb, INC. | $247.68 | 2021-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $216.67 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $214.45 | 2023-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $179.94 | 2024 | Zoryve |
| Incyte Corporation | $173.66 | 2022-2024 | Opzelura |
| Amgen INC. | $156.04 | 2021-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $88.77 | 2023-2024 | Vtama |
| Genzyme Corporation | $80.68 | 2021-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $57.70 | 2021 | |
| Kyowa Kirin, INC. | $54.47 | 2021-2022 | |
| Galderma Laboratories, L.P. | $42.99 | 2021-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.08 | 2022-2023 | Spevigo |
| Janssen Scientific Affairs, LLC | $22.29 | 2022 | |
| Organon LLC | $21.09 | 2025 | Vtama |
| Pfizer INC. | $20.70 | 2024 | |
| Almirall LLC | $16.11 | 2022 | |
| Verrica Pharmaceuticals INC. | $15.50 | 2023 | Ycanth |
| Biofrontera INC. | $7.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hui Ling Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.